Article info

Download PDFPDF
Extended report
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles

Authors

  1. Correspondence to Professor Chris Chamberlain, UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK; Chris.Chamberlain{at}ucb.com
View Full Text

Citation

Chamberlain C, Colman PJ, Ranger AM, et al
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles

Publication history

  • Received November 1, 2017
  • Revised June 1, 2017
  • Accepted June 10, 2017
  • First published August 5, 2017.
Online issue publication 
October 09, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.